Contineum Therapeutics, Inc.
CTNM
$4.62
$0.245.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -100.00% | -- | -- | -- |
| SG&A Expenses | 81.93% | 52.54% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.03% | 46.57% | -- | -- | -- |
| Operating Income | -416.57% | -314.36% | -- | -- | -- |
| Income Before Tax | -282.38% | -251.02% | -- | -- | -- |
| Income Tax Expenses | -- | -126.35% | -- | -- | -- |
| Earnings from Continuing Operations | -285.99% | -254.34% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -285.99% | -254.34% | -- | -- | -- |
| EBIT | -416.57% | -314.36% | -- | -- | -- |
| EBITDA | -411.19% | -310.80% | -- | -- | -- |
| EPS Basic | -445.15% | -246.65% | -- | -- | -- |
| Normalized Basic EPS | -148.03% | -175.26% | -- | -- | -- |
| EPS Diluted | -214.92% | -10.26% | -- | -- | -- |
| Normalized Diluted EPS | -523.21% | -734.99% | -- | -- | -- |
| Average Basic Shares Outstanding | 736.63% | 487.85% | -- | -- | -- |
| Average Diluted Shares Outstanding | 575.35% | 373.69% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |